In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.

TitleIn vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.
Publication TypeJournal Article
Year of Publication2005
AuthorsShah K, Tung C-H, Breakefield XO, Weissleder R
JournalMol Ther
Volume11
Issue6
Pagination926-31
Date Published2005 Jun
ISSN1525-0016
KeywordsAnimals, Apoptosis, Apoptosis Regulatory Proteins, Caspase 3, Caspases, Genetic Therapy, Genetic Vectors, Glioma, Humans, Luciferases, Luminescent Measurements, Membrane Glycoproteins, Mice, TNF-Related Apoptosis-Inducing Ligand, Tumor Burden, Tumor Necrosis Factor-alpha
Abstract

Therapeutic proteins with specific effector functions play an increasingly important role in drug therapy. For example, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) predominantly kills cancer cells, while sparing normal cells. Here, we report the use of a secreted version of TRAIL as a therapeutic protein that induces apoptosis and kills surrounding cells in vivo, thus resulting in the dramatic reduction of glioma burden in mouse tumor models. Using a caspase-3-activatable aminoluciferin, we were able to show the induction of apoptosis specifically in S-TRAIL vector-infected gliomas. We also show that S-TRAIL-mediated apoptosis and resulting changes in tumor burden can be imaged in the same animal by dual-substrate bioluminescence imaging. The use of S-TRAIL as a therapeutic protein and the ability to image noninvasively both apoptosis and any other cellular events in real time have important clinical implications.

DOI10.1016/j.ymthe.2005.01.017
Alternate JournalMol Ther
PubMed ID15922963
Grant ListCA86355 / CA / NCI NIH HHS / United States
CA99385 / CA / NCI NIH HHS / United States
P50CA86355 / CA / NCI NIH HHS / United States
R24CA92782 / CA / NCI NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065